Adaptive Radiotherapy in Head and Neck Tumor Patients
Recruiting now · Not applicable
Conditions studied: Head and Neck Neoplasms, Head and Neck Cancer, Adaptive Radiotherapy, Optimization
In brief
Most newly diagnosed oropharyngeal and hypopharyngeal cancers are treated with radiochemotherapy with curative intent. If the field-set UP margins are broad, the consequence may be that quality of life is impaired. The study group of Nutting et al. (2023) investigated this year whether dysphagia-optimized intensity-modulated radiotherapy can reduce the radiation dose to structures associated with dysphagia and aspiration and improve swallowing function compared to standard IMRT (Nutting C, Finneran L, Roe J, Petkar I, Rooney K, Hall E; DARS Triallist Group. Dysphagia-optimized intensity-modulated radiotherapy versus standard radiotherapy in patients with pharyngeal cancer - Authors' reply. Lancet Oncol. 2023 Oct;24(10):e398. doi: 10.1016/S1470-2045(23)00457-6. PMID: 37797636.) The study group concluded that the results suggest that dysphagia-optimized IMRT improves patient-reported swallowing function compared to standard IMRT. DO-IMRT should be considered the new standard of care for patients receiving radiotherapy for pharyngeal cancer, and ART could further improve outcomes.
Key facts
- Study ID
- NCT06216171
- Run by
- University Hospital, Essen
- People needed
- 30
- Starts
- 2024-01-25
- Expected to finish
- 2028-01-30
- Last updated by the study team
- 2024-09-27
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- ECOG 0/1 No prior cancer treatment
You may not qualify if…
- ECOG 2-4 Prior cancer treatment
Where it is running
- Maja Guberina — Essen, Germany (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.